Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Common Equity: 2016-2025

Historic Common Equity for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Sep 2025 value amounting to $313.7 million.

  • Rocket Pharmaceuticals' Common Equity fell 4.88% to $313.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $313.7 million, marking a year-over-year decrease of 4.88%. This contributed to the annual value of $463.2 million for FY2024, which is 5.96% down from last year.
  • As of Q3 2025, Rocket Pharmaceuticals' Common Equity stood at $313.7 million, which was down 11.45% from $354.2 million recorded in Q2 2025.
  • In the past 5 years, Rocket Pharmaceuticals' Common Equity ranged from a high of $541.1 million in Q3 2023 and a low of $313.7 million during Q3 2025.
  • Moreover, its 3-year median value for Common Equity was $412.1 million (2025), whereas its average is $417.7 million.
  • In the last 5 years, Rocket Pharmaceuticals' Common Equity skyrocketed by 100.82% in 2021 and then crashed by 39.05% in 2024.
  • Rocket Pharmaceuticals' Common Equity (Quarterly) stood at $454.7 million in 2021, then grew by 7.69% to $489.7 million in 2022, then climbed by 0.59% to $492.6 million in 2023, then dropped by 5.96% to $463.2 million in 2024, then declined by 4.88% to $313.7 million in 2025.
  • Its last three reported values are $313.7 million in Q3 2025, $354.2 million for Q2 2025, and $412.1 million during Q1 2025.